CTNM Contineum Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1855175 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-6.9%
TTM EPS YoY21.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-29.8%
ROA-28.3%
ROIC (approx.)-37.1%
Asset turnover—
Leverage & solvency
Liabilities / assets4.5%
Debt / equity0.00x
Current ratio31.11x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | $0 |
| R&D expense | $51.52M | $38.42M |
| SG&A expense | $16.54M | $12.47M |
| Operating income | -$68.06M | -$50.89M |
| Interest expense | — | $0 |
| Pretax income | -$60.14M | -$42.26M |
| Income tax | $0 | $0 |
| Net income | -$59.98M | -$42.26M |
| EBITDA | -$67.74M | -$50.64M |
| EPS (basic) | -2.17 | -2.18 |
| EPS (diluted) | -2.17 | -2.18 |
| Weighted avg. shares (diluted) | 27.70M | 19.35M |
| Balance sheet | ||
| Cash & equivalents | $75.60M | $21.94M |
| Short-term investments | $187.29M | $182.82M |
| Current assets | $267.92M | $206.39M |
| PP&E, net | $830,000 | $989,000 |
| Total assets | $276.64M | $212.85M |
| Current liabilities | $9.74M | $9.97M |
| Total liabilities | $15.65M | $14.78M |
| Shareholders' equity | $260.99M | $198.07M |
| Cash flow statement | ||
| Operating cash flow | -$55.31M | -$32.84M |
| Capital expenditure | $231,000 | $514,000 |
| Free cash flow | -$55.54M | -$33.36M |
| Investing cash flow | -$3.71M | -$69.74M |
| Financing cash flow | $112.69M | $109.00M |
| Depreciation & amortization | $323,000 | $258,000 |
| Stock-based compensation | $10.04M | $6.80M |
Free plan shows the latest 2 periods; Pro shows all 3 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.